Shares of GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) were up 0.4% during mid-day trading on Monday . The company traded as high as $20.85 and last traded at $20.67. Approximately 1,298,200 shares changed hands during mid-day trading, an increase of 2,574% from the average daily volume of 48,553 shares. The stock had previously closed at $20.59.
GENMAB A/S/S Price Performance
The business’s 50-day simple moving average is $23.59 and its 200-day simple moving average is $26.08.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Read More
- Five stocks we like better than GENMAB A/S/S
- Pros And Cons Of Monthly Dividend Stocks
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- What are earnings reports?
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
